The interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1) represents a mechanism of immune escape and a therapeutic target for poor-prognosis malignancies, such as melanoma and non-small-cell lung cancer (NSCLC) [9]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.